ADC Review / Journal of Antibody-drug Conjugates

Chandler,  AZ 
United States
  • Booth: 954

ADC Review / Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed journal dedicated to serving more than 16,000 large to small pharma/biotech, equipment manufacturers, contract developers, clinicians/physicians, payers, and regulatory and government professionals that represent the leading minds in ADC development. The Journal, which focuses on Antibody-drug Conjugates and targeted therapies in oncology and hematology, publishes peer reviewed research, commentaries, news features, discussions, editorials/Op-Ed’s and blogs on topics relevant to a broad international readership. With 2 approved agents, more than 50 antibody-drug conjugates in clinical trials and a growing preclinical pipeline of nearly 100 ADCs, the journal reports about the latest advances and the progressive innovations in the development of these next-generation targeted drugs.